{"id":"cetiedil","rwe":[{"pmid":"20550121","year":"2010","title":"Palladium-catalyzed asymmetric allylic alkylation of 2-acylimidazoles as ester enolate equivalents.","finding":"","journal":"Journal of the American Chemical Society","studyType":"Clinical Study"},{"pmid":"15121096","year":"2004","title":"Pharmacology of the human red cell voltage-dependent cation channel; Part I. Activation by clotrimazole and analogues.","finding":"","journal":"Blood cells, molecules & diseases","studyType":"Clinical Study"},{"pmid":"14729097","year":"2004","title":"Inhibition of the antigen-induced activation of RBL-2H3 cells by cetiedil and some of its analogues.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"14729096","year":"2004","title":"Inhibition of the antigen-induced activation of RBL-2H3 cells by charybdotoxin and cetiedil.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"11860149","year":"2002","title":"An analysis of the mechanism by which cetiedil inhibits sickling.","finding":"","journal":"Life sciences","studyType":"Clinical Study"}],"tags":[{"label":"cetiedil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C04AX26","category":"atc"},{"label":"Active","category":"status"},{"label":"Antisickling Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["cetiedil citrate","cetiedil"],"offLabel":[],"synonyms":["cetiedil citrate","cetiedil"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cetiedil","explanation":"This means that CETIEDIL may help increase the levels of certain chemicals in the brain that help regulate mood and other functions. By doing so, it may help alleviate symptoms of certain conditions. However, the exact way CETIEDIL works is not well understood.","oneSentence":"CETIEDIL is thought to work by inhibiting the breakdown of certain neurotransmitters in the body.","technicalDetail":"CETIEDIL is believed to act as a reversible inhibitor of catechol-O-methyltransferase (COMT), an enzyme involved in the degradation of catecholamine neurotransmitters such as dopamine, norepinephrine, and epinephrine."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/580","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CETIEDIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:30:38.941361","biosimilars":[],"competitors":[{"drugName":"phenoxybenzamine","drugSlug":"phenoxybenzamine","fdaApproval":"1953-01-26","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"cetiedil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phenoxybenzamine","brandName":"phenoxybenzamine","genericName":"phenoxybenzamine","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005398","UNII":"621RT200TO","CHEBI":"CHEBI:34619","INN_ID":"3171","RXNORM":"20609","UMLSCUI":"C0055146","ChEMBL_ID":"CHEMBL419380","KEGG_DRUG":"D03450","DRUGBANK_ID":"DB13753","PUBCHEM_CID":"66384","SECONDARY_CAS_RN":"16286-69-4","MESH_SUPPLEMENTAL_RECORD_UI":"C006955"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":77,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"C04AX26","allCodes":["C04AX26"]},"biosimilarFilings":[],"recentPublications":[{"date":"2010 Jul 7","pmid":"20550121","title":"Palladium-catalyzed asymmetric allylic alkylation of 2-acylimidazoles as ester enolate equivalents.","journal":"Journal of the American Chemical Society"},{"date":"2004 May-Jun","pmid":"15121096","title":"Pharmacology of the human red cell voltage-dependent cation channel; Part I. Activation by clotrimazole and analogues.","journal":"Blood cells, molecules & diseases"},{"date":"2004 Jan 12","pmid":"14729097","title":"Inhibition of the antigen-induced activation of RBL-2H3 cells by cetiedil and some of its analogues.","journal":"European journal of pharmacology"},{"date":"2004 Jan 12","pmid":"14729096","title":"Inhibition of the antigen-induced activation of RBL-2H3 cells by charybdotoxin and cetiedil.","journal":"European journal of pharmacology"},{"date":"2002 Jan 18","pmid":"11860149","title":"An analysis of the mechanism by which cetiedil inhibits sickling.","journal":"Life sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CETIEDIL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CETIEDIL is a small molecule drug in the cetiedil class, but specific details about its development, approval status, and commercial status are not available. As a result, there is limited information about its target, approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the clinical use and safety profile of CETIEDIL. Its mechanism of action and key safety considerations are also unclear. Overall, CETIEDIL appears to be a relatively unknown drug.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}